126 related articles for article (PubMed ID: 17979569)
21. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
22. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
Grillo-López AJ
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025
[TBL] [Abstract][Full Text] [Related]
23. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
Weber T; Bötticher B; Arndt MA; Mier W; Sauter M; Exner E; Keller A; Krämer S; Leotta K; Wischnjow A; Grosse-Hovest L; Strumberg D; Jäger D; Gröne HJ; Haberkorn U; Brem G; Krauss J
Cancer Lett; 2016 Oct; 381(2):296-304. PubMed ID: 27524505
[TBL] [Abstract][Full Text] [Related]
24. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
Wiseman GA; Witzig TE
Cancer Biother Radiopharm; 2005 Apr; 20(2):185-8. PubMed ID: 15869453
[TBL] [Abstract][Full Text] [Related]
25. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography.
Perk LR; Visser OJ; Stigter-van Walsum M; Vosjan MJ; Visser GW; Zijlstra JM; Huijgens PC; van Dongen GA
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1337-45. PubMed ID: 16832633
[TBL] [Abstract][Full Text] [Related]
26. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
Jacobs SA; Vidnovic N; Joyce J; McCook B; Torok F; Avril N
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7146s-7150s. PubMed ID: 16203814
[TBL] [Abstract][Full Text] [Related]
27. p53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan.
Su H; Ganapathy S; Li X; Yuan ZM; Ha CS
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1116-1122. PubMed ID: 26025778
[TBL] [Abstract][Full Text] [Related]
28. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
Wiseman GA; White CA; Witzig TE; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Grillo-López AJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3281s-3286s. PubMed ID: 10541376
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma.
Otte A
Hell J Nucl Med; 2008; 11(1):12-5. PubMed ID: 18392220
[TBL] [Abstract][Full Text] [Related]
30. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
Jacene HA; Filice R; Kasecamp W; Wahl RL
J Nucl Med; 2007 Nov; 48(11):1767-76. PubMed ID: 17942813
[TBL] [Abstract][Full Text] [Related]
31. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
[TBL] [Abstract][Full Text] [Related]
32. Development of 131I-tositumomab.
Lewington V
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S50-6. PubMed ID: 15786026
[TBL] [Abstract][Full Text] [Related]
33. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
Witzig TE; White CA; Gordon LI; Wiseman GA; Emmanouilides C; Murray JL; Lister J; Multani PS
J Clin Oncol; 2003 Apr; 21(7):1263-70. PubMed ID: 12663713
[TBL] [Abstract][Full Text] [Related]
34. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma.
Scheidhauer K; Wolf I; Baumgartl HJ; Von Schilling C; Schmidt B; Reidel G; Peschel C; Schwaiger M
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1276-82. PubMed ID: 12271407
[TBL] [Abstract][Full Text] [Related]
35. Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin).
White CA
J Exp Ther Oncol; 2004 Dec; 4(4):305-16. PubMed ID: 15844660
[TBL] [Abstract][Full Text] [Related]
36. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
[TBL] [Abstract][Full Text] [Related]
37. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in (131)I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma.
Boucek JA; Turner JH
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):458-69. PubMed ID: 15821965
[TBL] [Abstract][Full Text] [Related]
38. Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen.
Theuer CP; Leigh BR; Multani PS; Allen RS; Liang BC
Biotechnol Annu Rev; 2004; 10():265-95. PubMed ID: 15504711
[TBL] [Abstract][Full Text] [Related]
39. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
Cremonesi M; Ferrari M; Grana CM; Vanazzi A; Stabin M; Bartolomei M; Papi S; Prisco G; Ferrucci PF; Martinelli G; Paganelli G
J Nucl Med; 2007 Nov; 48(11):1871-9. PubMed ID: 17978355
[TBL] [Abstract][Full Text] [Related]
40. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
Hendrix CS; de Leon C; Dillman RO
Clin J Oncol Nurs; 2002; 6(3):144-8. PubMed ID: 11998607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
